BioNTech Net Interest Income from 2010 to 2026

Stocks . USA . 
Stock . BioNTech SE
BNTX Stock  USD 90.10  -0.74  -0.81%   
Net Interest Income is reflecting a rebounding pattern with measured volatility. Estimates place it near approximately 513.2 M for the current fiscal year. Net Interest Income is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. View All Fundamentals
 
Net Interest Income  
 First Reported
2019-03-31
 Previous Quarter
-3.3 M
 Current Value
-300 K
 Quarterly Volatility
71.3 M
Macro event markers
 
Covid
 
Interest Hikes
This statements view for BioNTech organizes long-term performance signals with capital structure context. The series highlights drivers like Net Interest Income of 513.2 M, Interest Income of 528.4 M or Discontinued Operations of 0.0 and ratios such as Price To Sales Ratio of 6.77, Dividend Yield of 0.011 or PTB Ratio of 1.07, complementing BioNTech Valuation and Volatility.
  
Build AI portfolio with BioNTech Stock
Compare BioNTech against competitors using BioNTech Correlation. This supports competitive context.
Analyzing BioNTech's Net Interest Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Interest Income has evolved provides context for assessing BioNTech's current valuation and future prospects.

Latest BioNTech's Net Interest Income Growth Pattern

Below is the plot of the Net Interest Income of BioNTech SE over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. BioNTech's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
Net Interest Income10 Years Trend
Slightly volatile
Compare to OthersAll Fundamentals
   Net Interest Income   
       Timeline  

BioNTech Net Interest Income Regression Statistics

Arithmetic Mean 121,761,559
Coefficient Of Variation 165.63
Mean Deviation 174,027,024
Median 1,404,000
Standard Deviation 201,676,845
Sample Variance40673.5T
Range539M
R-Value 0.79
Mean Square Error16043.4T
R-Squared 0.63
Significance 0.0001
Slope 31,705,071
Total Sum of Squares650776.8T

BioNTech Net Interest Income History

2026513.2 M
2025488.8 M
2024425 M
2023349.7 M
2022311.4 M
2021-25.8 M
2020-3.5 M

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Biontech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3082 people. Downside history and drawdown behavior provide context for risk expectations in BioNTech. Downside profile remains relatively contained. BioNTech has a market cap of 21.05 B, P/E of 5.19, ROE of -3.04%.

Methodology

Unless otherwise specified, financial data for BioNTech SE is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. BioNTech (USA Stocks:BNTX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: This report is built using public filings and market reference sources and official sources including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Normalization for analytical consistency may introduce small timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

BioNTech SE is covered by 20 analysts. 10 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Jefferies, Raymond James, Goldman Sachs, Bank of America Securities, Morgan Stanley, Deutsche Bank, Wells Fargo Securities, BMO Capital Markets, RBC Capital Markets, among others. Updates may occur throughout the day.

BioNTech Stock is Curated By:

Raphi ShpitalnikRaphi Shpitalnik ยท Junior Member of Macroaxis Editorial Board

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
BACBank of America

More Resources for BioNTech Stock Analysis

A structured review of BioNTech SE often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for BioNTech SE Stock. Highlighted below are reports that provide context for BioNTech SE Stock:
How To Invest In BioNTech
Details
Is BioNTech Stock a good investment?
Details
What is BioNTech's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Compare BioNTech against competitors using BioNTech Correlation. This supports competitive context.
Analysis related to BioNTech should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
 Quarterly Earnings Growth
-0.43
 Earnings Share
-2.75
 Revenue Per Share
13.137
 Quarterly Revenue Growth
0.22
 Return On Assets
-0.02
Investors evaluate BioNTech SE using market value and book value, each describing different facets of the business. BioNTech's market capitalization is 21.05 B. A P/B ratio of 0.99 suggests BioNTech trades near or below book value. Enterprise value stands at 4.61 B. Intrinsic value is an estimate of what BioNTech's fundamentals imply, and it may differ from market and book figures. Analytical frameworks help compare those viewpoints.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Analysis
Details
Earnings
Projections
Details
Value and price for BioNTech are related but not identical, and they can diverge across cycles. For BioNTech, key inputs include a P/E ratio of 5.19, a P/B ratio of 0.99, a profit margin of -18.13%, and ROE of -3.04%. By contrast, market price reflects the level where buyers and sellers transact.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY